Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study

被引:16
|
作者
Zettl, Uwe K. [1 ]
Bauer-Steinhusen, Ulrike [2 ]
Glaser, Thomas [2 ]
Hechenbichler, Klaus [3 ]
Limmroth, Volker [4 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Rostock, Germany
[2] Bayer Vital GmbH, Immunol & Ophthalmol, Med Neurol, Leverkusen, Germany
[3] Inst Dr Schauerte, Oberhaching, Germany
[4] Stadt Klinikum Koln Merheim, Klin Neurol, Cologne, Germany
来源
BMC NEUROLOGY | 2013年 / 13卷
关键词
Adherence; Interferon beta-1b; Non-interventional study; Electronic diary; Multiple sclerosis; Immunomodulation; DEPRESSIVE SYMPTOMS; CES-D; THERAPY; POPULATION; VALIDATION; MEDICATION; IMPACT; COSTS; DRUGS; CARE;
D O I
10.1186/1471-2377-13-117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis is a chronic, incurable, demyelinating disease that requires long-term treatment. Rates of non-adherence to prescribed therapy of up to 50% have been reported for chronic diseases. Strategies to improve treatment adherence are therefore of the utmost importance. This study will evaluate the effect of using electronic and paper diaries on treatment adherence to interferon beta-1b in patients with a first clinical isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). Here we report on the study design and results of baseline assessments. Methods: Patients were recruited into a prospective national multicenter cohort study for an observational period of 2 years. At the start of the study, patients opted to use a digital (DiD) or paper diary (PD) to document self-administered injections of interferon beta-1b. Adherence to treatment will be assessed on the dropout rate at the end of the observation period and on the regularity of injections every other day at 6-month intervals. Patient-related health outcomes will also be evaluated. Results: 700 patients with a mean age of 38.3 (SD 10.3) years and a mean duration of disease since diagnosis of 3.6 (SD 5.9) years were enrolled. 383 patients opted for the digital diary, 192 of which included an injection reminder. Significantly more male than female patients opted for the DiD. Only gender was identified as a factor influencing the decision for DiD or PD. Based on rating scales, a significantly higher proportion of women had depressive comorbidities at baseline. Conclusions: Demographic characteristics of the two cohorts were similar at baseline. More women chose a paper diary, and more had depression at baseline. These imbalances will be addressed in the analysis of the study as possible confounders influencing long-term treatment adherence in the digital and paper diary cohorts.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Effect of interferon beta-1b on the nonverbal learning and sustained attention in patients with multiple sclerosis
    Kukakowska, Alina
    Halicka, Dorota
    Drozdowski, Wieslaw
    AKTUALNOSCI NEUROLOGICZNE, 2005, 5 (04): : 265 - 270
  • [22] Interferon Beta-1b May Reverse Axonal Dysfunction in Multiple Sclerosis
    Takeuchi, C.
    Ota, K.
    Ono, Y.
    Iwata, M.
    NEURORADIOLOGY JOURNAL, 2007, 20 (05) : 531 - 540
  • [23] Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b
    Bitsch, A
    Dressel, A
    Meier, K
    Bogumil, T
    Deisenhammer, F
    Tumani, H
    Kitze, B
    Poser, S
    Weber, F
    JOURNAL OF NEUROLOGY, 2004, 251 (12) : 1498 - 1501
  • [24] Neutralizing antibodies (NABS) and interferon beta-1B therapy of multiple sclerosis
    Horowski, R
    Stürzebecker, CS
    Kapp, JF
    FUNCTIONAL NEUROLOGY, 2001, 16 (02) : 117 - 128
  • [25] Autoimmune events during interferon beta-1b treatment for multiple sclerosis
    Durelli, L
    Ferrero, B
    Oggero, A
    Verdun, E
    Bongioanni, MR
    Gentile, E
    Isoardo, GL
    Ricci, A
    Rota, E
    Bergamasco, B
    Durazzo, M
    Saracco, G
    Biava, MA
    Brossa, PC
    Giorda, L
    Pagni, R
    Aimo, G
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 162 (01) : 74 - 83
  • [26] Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: An open-label prospective 1 year study
    Flechter, Shlomo
    Vardi, Jacob
    Finkelstein, Yoram
    Pollak, Lea
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (06): : 457 - 459
  • [27] A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector
    Farej, Ryan
    Rametta, Mark
    La Rose, Anneliese
    Quillen, Apryl
    McLeod, Kim
    NEUROLOGY AND THERAPY, 2022, 11 (01) : 373 - 384
  • [28] SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology
    Christian P Kamm
    Heinrich P Mattle
    Trials, 10
  • [29] Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b
    Andreas Bitsch
    Alexander Dressel
    Kathrin Meier
    Timon Bogumil
    Florian Deisenhammer
    Hayrettin Tumani
    Bernd Kitze
    Sigrid Poser
    Frank Weber
    Journal of Neurology, 2004, 251 : 1498 - 1501
  • [30] Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis
    de Freitas Rosa, Dario Junior
    Toledo Matias, Fernanda de Abreu
    Cedrim, Samya Diegues
    Machado, Ronaldo Figueiredo
    Montenegro de Sa, Alessandra Almeida
    Piccinini Silva, Vania Carolina
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2011, 86 (02) : 336 - 338